Massive Bio has been named an OpenAI Select Partner to expand its AI platform that matches cancer patients with clinical trials, converting dense trial eligibility criteria into structured data for faster review by oncologists.
Hackensack Meridian Health is the first U.S. health system to earn the Joint Commission's new Responsible Use of AI in Healthcare Certification, a governance credential that checks how hospitals oversee AI tools rather than approving any single algorithm.
Insilico Medicine has launched a Phase III trial of rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, making it one of the only AI-discovered therapeutics to reach late-stage trials as the industry still awaits its first full FDA approval.
A phishing email at healthcare AI vendor Xsolis led to a breach exposing records for 1.4 million patients across seven health systems including Mayo Clinic, underscoring the risk of concentrating sensitive data with third-party AI platforms.
DeepHealth, a RadNet subsidiary, has received FDA 510(k) clearance for an AI system that detects breast ultrasound lesions and drafts structured reports, with validation data showing over 98% localization accuracy and a 37% cut in interpretation time.
Butterfly Network's FDA-cleared Gestational Age Tool uses AI to estimate how far along a pregnancy is from a simple ultrasound sweep in under two minutes, and is already deployed in Malawi and Uganda with Gates Foundation backing.
A new report from Disability Belongs and the Consumer Technology Association, released August 4, 2026, documents how people with disabilities are using AI tools right now across transportation, household management, healthcare, and employment.
Proscia has won FDA clearance for its Concentriq AP-Dx digital pathology platform to include a Predetermined Change Control Plan, letting it add support for new scanners without filing separate approvals each time.
Dartmouth's Therabot, tested in a 210-person randomized trial published March 2025 in NEJM AI, showed a 51% symptom reduction for depression and 31% for anxiety, offering the first clinical-trial evidence that a purpose-built AI chatbot can meaningfully treat mental illness.
After Samsung, Apple, PranaQ, and Happy Health all won FDA clearances for AI-powered sleep apnea detection on wearables in 2025, the FDA issued new January 2026 guidance clarifying which wellness claims wearables can make without full medical-device review.